Characteristic | Total = 3019 | Discontinued = 351 | Continued = 2668 | P |
---|---|---|---|---|
N (%) | N (%) | N (%) | ||
Gender | .083 | |||
Male | 2605 (86.3) | 292 (83.2) | 2313 (86.7) | |
Female | 414 (13.7) | 59 (16.8) | 355 (13.3) | |
Age (years) | .021 | |||
≤ 45 | 2240 (75.0) | 244 (69.9) | 1996 (75.7) | |
> 45 | 746 (25.0) | 105 (30.1) | 641 (24.3) | |
Mode of transmission | .598 | |||
MSM/Bisexual | 1038 (34.4) | 115 (32.8) | 923 (34.6) | |
Heterosexual | 1683 (55.7) | 198 (56.4) | 1485 (55.7) | |
IDU | 6 (0.2) | 1 (0.3) | 5 (0.2) | |
Other | 62 (2.1) | 11 (3.1) | 51 (1.9) | |
Unknown | 230 (7.6) | 26 (7.4) | 204 (7.6) | |
Pretreatment CD4 cell count (cells/mm3) | .011 | |||
< 200 | 723 (25.6) | 104 (31.4) | 619 (24.8) | |
≥ 200 | 2103 (74.4) | 227 (68.6) | 1876 (75.2) | |
Pretreatment viral load (copies/mL) | .213 | |||
< 100,000 | 1262 (45.0) | 135 (41.7) | 1127 (45.4) | |
≥ 100,000 | 1545 (55.0) | 189 (58.3) | 1356 (54.6) | |
AIDS diagnosis | .006 | |||
Yes | 793 (26.3) | 114 (32.5) | 679 (25.4) | |
No | 2226 (73.7) | 237 (67.5) | 1989 (74.6) | |
ART regimen type | <.001 | |||
InSTI | 1135 (37.6) | 63 (17.9) | 1072 (40.2) | |
InSTI/PI | 6 (0.2) | 1 (0.3) | 5 (0.2) | |
NNRTI | 798 (26.4) | 109 (31.1) | 689 (25.8) | |
PI | 1080 (35.8) | 178 (50.7) | 902 (33.8) | |
Type of initial ART | <.001 | |||
EFV/TDF/FTC | 750 (24.8) | 101 (28.8) | 649 (24.3) | |
LPV/r/TDF/FTC | 743 (24.6) | 121 (34.5) | 622 (23.3) | |
EVG/c/TDF/FTC | 680 (22.5) | 39 (11.1) | 641 (24.0) | |
DTG/TDF/FTC | 351 (11.6) | 10 (2.8) | 341 (12.8) | |
DRV/r/TDF/FTC | 276 (9.1) | 34 (9.7) | 242 (9.1) | |
RAL/TDF/FTC | 65 (2.2) | 12 (3.4) | 53 (2.0) | |
LPV/r/ZDV/3TC | 53 (1.8) | 21 (6.0) | 32 (1.2) | |
EFV/ZDV/3TC | 39 (1.3) | 7 (2.0) | 32 (1.2) | |
Other | 62 (2.1) | 6 (1.7) | 56 (2.1) | |
Year of ART initiation | .031 | |||
2011–2014 | 1495 (49.5) | 193 (55.0) | 1302 (48.8) | |
2015–2017 Feb | 1524 (50.5) | 158 (45.0) | 1366 (51.2) |